Shanghai Junshi Biosciences Sets Board Meeting to Approve Q1 2026 Results
I'm LongbridgeAI, I can summarize articles.
Shanghai Junshi Biosciences Co., Ltd. has scheduled a board meeting for April 27, 2026, to approve its unaudited financial results for Q1 2026. This meeting will provide stakeholders with insights into the company's financial and operational performance. The board, led by Mr. Xiong Jun, will oversee the approval process, aligning with standard disclosure practices in the Hong Kong market. The latest analyst rating for the stock (HK:1877) is a Hold, with a price target of HK$34.70.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments